Creatinine was a metabolism molecule product
which is produced from the muscle metabolism.
Creatinine was an important molecule in the process
of energy production in the muscle, it is produced
from creatine. Every day, about 2% of the creatine
in the body, it was converted into creatinine form
(Horio, 2014). This molecules are transported into
the kidneys through blood vessel. The kidneys filter
out and remove of the creatinine in the urine. The
creatinine was a reliable indicator to determine the
function of.kidney.
The results of rat blood serum testing in each
group were statistically analyzed by spss to compare
the differences between treatment groups to negative
control and positive control. Based on Table 1, it
showed that the effective dose of ethanol extract
celery herb was 150 mg/kg BW and it showed dose
dependent manner. Level of urea in treatment group
of ethanol extract 150 mg/kgBW was 40.6 showed
there was no different to positive control (P>0.05)
and significant different to negative control (P<0.05).
Table 2 showed that effective dose of ethanol
extract celery herb to creatinine level of rat induced
ethylen glycol was 150 mg/kgBW with level of
creatinine was 0.30. Level of creatinine was not
different to positive control (P>0.05) and significant
different to negative control (P<0.05). Content of
flavonoids in ethanol extract celery herb prevents
oxidative stress in the kidney by increasing
glutathione s-transferase (GSH) antioxidant activity ,
increasing GSH synthesis and trapping directly ROS
formed by donating H atoms to free radicals resulting
in non-reactive free radical compounds and non-
reactive radical flavonol compounds that can
improve kidney function (Kang et al, 2016). In this
research, elevation of urea and creatinine were
decreased by treatment with ethanol extract celery
herb and thereby improved kidney functions in
nephrolithiatic condition.
4 CONCLUSION
Ethanol extract of celery herb at the dose of 50,100
and 150 mg/kgbw have effect in decreasing level of
urea and creatinine. Treatment dose which has
effective activity was 150 mg/kgbw and it showed
dose dependent manner.
ACKNOWLEDGEMENT
Research funded by Universitas Sumatera Utara in
accordance to the contract of research
implementation TALENTA Universitas Sumatera
Utara funding year 2018 No. 2590/UN5.1.R/PPM/
2018, date : 16 March 2018.
REFERENCES
Bent, S. and Ko, R., 2004. Commonly used herbal
medicines in the United States: a review. The American
journal of medicine, 116(7), pp.478-485.
Brikowski, T.H., Lotan, Y. and Pearle, M.S., 2008.
Climate-related increase in the prevalence of
urolithiasis in the United States. Proceedings of the
National Academy of Sciences.
Butterweck, V. and Khan, S.R., 2009. Herbal medicines in
the management of urolithiasis: alternative or
complementary?. Planta medica, 75(10), p.1095.
Coe, F.L., Parks, J.H. and Asplin, J.R., 1992. The
pathogenesis and treatment of kidney stones. New
England Journal of Medicine, 327(16), pp.1141-1152.
Curhan, G.C., Willett, W.C., Speizer, F.E., Spiegelman, D.
and Stampfer, M.J., 1997. Comparison of dietary
calcium with supplemental calcium and other nutrients
as factors affecting the risk for kidney stones in
women. Annals of Internal Medicine, 126(7), pp.497-
504.
Hooper, L., Kroon, P.A., Rimm, E.B., Cohn, J.S., Harvey,
I., Le Cornu, K.A., Ryder, J.J., Hall, W.L. and Cassidy,
A., 2008. Flavonoids, flavonoid-rich foods, and
cardiovascular risk: a meta-analysis of randomized
controlled trials. The American journal of clinical
nutrition, 88(1), pp.38-50.
Horio, M., 2014. New topics regarding equations for GFR
estimation based on serum creatinine and cystatin C.
Rinsho byori. The Japanese journal of clinical
pathology, 62(2), pp.153-162.
Kang, J.T., Moon, J.H., Choi, J.Y., Park, S.J., Kim, S.J.,
Saadeldin, I.M. and Lee, B.C., 2016. Effect of
antioxidant flavonoids (quercetin and taxifolin) on in
vitro maturation of porcine oocytes. Asian-
Australasian journal of animal sciences, 29(3),
p.352.
López, M. and Hoppe, B., 2010. History, epidemiology and
regional diversities of urolithiasis. Pediatric
nephrology, 25(1), p.49.
Meier, J.J., Nauck, M.A., Kranz, D., Holst, J.J., Deacon,
C.F., Gaeckler, D., Schmidt, W.E. and Gallwitz, B.,
2004. Secretion, degradation, and elimination of
glucagon-like peptide 1 and gastric inhibitory
polypeptide in patients with chronic renal
insufficiency and healthy control subjects. Diabetes,
53(3), pp.654-662.
Meier, J.J., Nauck, M.A., Kranz, D., Holst, J.J., Deacon,
C.F., Gaeckler, D., Schmidt, W.E. and Gallwitz, B.,